Sirodrol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sirodrol

What is Sirodrol? A Foundational Overview

Property Description
Active ingredient Prednisolone Acetate (C23H30O6)
Form Ophthalmic suspension (eye drops)
Pharmacological class Corticosteroid / Glucocorticoid
General purpose Suppression of inflammation and allergy
Origin Synthetic (ester derivative)

What Type of Drug is Sirodrol (Prednisolone Acetate)?

Sirodrol is a pharmaceutical preparation containing the active ingredient Prednisolone Acetate, which is classified as a potent synthetic glucocorticoid and a high-level corticosteroid. This classification means the medication is structurally related to cortisol, a hormone naturally produced by the body, and its primary function is to modulate the body's inflammatory response. The active agent is an ester derivative of the base compound prednisolone, manufactured specifically to enhance its therapeutic action and stability in the ophthalmic preparation. This use of an ester form is clinically recognized for providing effective, localized control over inflammatory conditions.

Composition and Physical Form of the Medication

The medication is a single-agent product where Prednisolone Acetate is the sole active pharmaceutical ingredient, typically formulated as an ophthalmic suspension, often referred to as eye drops. This preparation method utilizes an aqueous vehicle designed to ensure the controlled and uniform delivery of the active agent to the surface, making it suitable for a topical ophthalmic route of administration. This class of medication is instrumental in controlling tissue reactions that cause redness, swelling, and pain. The benefit of this topical, single-agent approach is minimizing systemic exposure while providing direct, localized action.

General Purpose and Core Physiological Effect

The core general purpose of Prednisolone Acetate is to manage and suppress acute or severe local inflammation, swelling, and related allergic symptoms, such as those that might occur following an injury or irritation. It achieves this by exerting a powerful anti-inflammatory and immunosuppressive effect at a cellular level. Functionally, this medication helps control excessive or harmful immune responses that lead to tissue irritation. This mechanism of action provides general relief by mitigating the underlying biological processes that cause symptoms like swelling and redness, making it effective in scenarios where significant tissue response is present.

Regulatory References

  1. MedlinePlus: Prednisolone Ophthalmic Drug Information
  2. DailyMed Label for Prednisolone Acetate Ophthalmic Suspension
  3. NIH DailyMed Label for Prednisolone Acetate Ophthalmic Suspension

What side effects are possible with Sirodrol?

Sirodrol is a proposed combination of Sirolimus (an immunosuppressant) and Drospirenone (a progestin hormone). Due to the powerful nature of its components, particularly Sirolimus, this medication carries a risk of serious side effects and requires careful safety monitoring.

Important Safety Considerations

Serious Risks

  • Increased Risk of Infection and Cancer: Sirolimus suppresses the immune system, which can increase the risk of serious bacterial, fungal, or viral infections, as well as the risk of certain cancers, such as lymphoma and skin cancer.
  • Blood Clots: Drospirenone is associated with an increased risk of blood clots (venous and arterial thromboembolism), which can lead to life-threatening conditions like deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or heart attack.
  • Hyperkalemia (High Potassium): Drospirenone has potassium-sparing properties. Patients, especially those with kidney impairment or those taking other potassium-increasing medications (e.g., ACE inhibitors), must have their potassium levels checked regularly to prevent severe hyperkalemia.
  • Kidney and Liver Function: Both components may affect kidney function (Sirolimus) or liver function (Drospirenone). Regular monitoring of liver and kidney laboratory values is necessary.

Common Side Effects

Patients taking Sirodrol may experience side effects commonly associated with its components. These are often manageable but should be discussed with a healthcare provider:

Sirolimus-Related (Immunosuppressant) Drospirenone-Related (Hormonal)
Headache, fever, chills Breast tenderness, menstrual changes
Nausea, diarrhea, constipation Headache, weight gain
High blood pressure, high cholesterol/triglycerides Mood changes, decreased libido
Swelling (edema) in the hands or feet Acne
Slower wound healing, mouth sores (canker sores) Nausea, abdominal pain

When to Seek Medical Attention: Immediately contact a healthcare professional if you experience signs of a blood clot (e.g., unexplained leg swelling, chest pain, sudden severe headache, or trouble breathing) or signs of infection (e.g., fever, persistent sore throat, or chills).

Overdose and Emergency Response

Sirodrol Overdose and When to Seek Help

The official regulatory profile for Sirodrol (Prednisolone Acetate ophthalmic suspension) addresses overdose primarily in the context of accidental swallowing, as acute overdosage from topical application is unlikely to occur. Due to the formulation and low volume, the accidental oral ingestion of the eye drops is not ordinarily expected to cause acute problems.

The following table summarizes the officially documented risks and regulator-mandated emergency actions for this product:

Domain Official Regulatory Statement
Overdose Risk Overdosage is primarily related to accidental oral ingestion of the solution.
Mandatory Action Immediate medical attention is required if the eye drops are swallowed.
Acute Symptoms Serious symptoms like trouble breathing or passing out require immediate contact with emergency services.
Procedural Step In the event of ingestion, one action is to drink fluids to dilute the product.

In cases of accidental ingestion, immediate action must be taken, including seeking emergency medical attention or contacting the Poison Help line. Treatment generally involves symptomatic and supportive therapy, as no specific antidote is known for this overdose scenario. No specific population-based considerations (e.g., pediatric or geriatric) are explicitly documented in the official overdose sections regarding severity or management.

Therapeutic Uses of Sirodrol

What Sirodrol Treats: Main Uses and Benefits

The primary role of Sirodrol (Prednisolone Acetate ophthalmic suspension) is centered on providing localized support for managing symptoms across conditions involving inflammatory or irritative processes of the eye. It is applied across domains where additional symptomatic support is needed, focusing exclusively on relief from signs of heightened physiological activity and localized discomfort.


This medication is commonly used across conditions presenting with acute episodes of inflammation, such as those that follow ophthalmic surgeries or occur after physical or chemical injury. The medication is relevant for addressing steroid-responsive inflammation of the palpebral and bulbar conjunctiva, the cornea, and the anterior segment of the globe, including non-infectious uveitis (like iritis and iridocyclitis) and allergic conjunctivitis characterized by heightened symptoms. Sirodrol's use in these scenarios contributes to easing the overall symptom load associated with tissue irritation.

The medication helps address symptom clusters that may become disruptive, such as intense burning, stinging, redness, and swelling. In clinical settings that involve acute or unstable symptom patterns, it may provide supportive relief that may help patients cope more steadily with symptom fluctuations.

“The medication may be relevant for helping ease distress from noticeable swelling and pain, supporting patients during difficult symptomatic episodes.”

Quick Fact: Relief for Inflammatory Symptoms Sirodrol is commonly used when symptoms intensify, assisting with supporting a sense of stability when acute inflammation and discomfort interfere with routine activities.

Regulatory References

  1. DailyMed listing published by the National Institutes of Health (NIH)

Eligibility and Restrictions for Use

Who can and cannot use Sirodrol?

Official regulatory labeling establishes clear boundaries for the use of Sirodrol. The medicine is contraindicated and must not be used by individuals with known or suspected hypersensitivity to Prednisolone Acetate or any component. Absolute exclusion also applies to patients with active ocular infections, specifically acute untreated purulent infections, mycobacterial disease, fungal diseases, and most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis.

Use is restricted and requires caution in specific populations. Patients with glaucoma or a history of elevated Intraocular Pressure (IOP) must be closely monitored. Great caution is also necessary for those with a history of herpes simplex infection or pre-existing thin corneal or scleral tissue. For pediatric patients, safety and efficacy are not established for all formulations, and prolonged use mandates IOP monitoring; very young children also carry a heightened risk of systemic effects like adrenal suppression. During pregnancy, use is conditional: it should only occur if the potential benefit justifies the potential risk to the fetus. Use during lactation is generally not recommended.

What should I know about interactions with other medicines?

The regulatory information for Sirodrol (Prednisolone Acetate ophthalmic suspension) confirms a specific pharmacokinetic interaction involving the drug's metabolic clearance. Co-administration with certain medicinal products classified as CYP3A inhibitors is officially documented to increase the overall systemic exposure of the active ingredient, prednisolone. This is due to the reduction of the active ingredient's clearance from the body.

Regulatory agencies specifically identify cobicistat-containing products as an example of strong CYP3A inhibitors that may lead to this exposure modification. The primary regulatory concern associated with this interaction is the heightened potential for systemic corticosteroid side-effects, including the development of symptoms related to Cushing's syndrome and the suppression of the adrenal gland function.

The combination of Sirodrol with CYP3A inhibitors is formally designated as one that should be avoided. If co-administration is deemed necessary by a prescriber, official regulatory guidance mandates close monitoring for signs of increased systemic corticosteroid effects. This single metabolic pathway defines the core constraint within the official interaction profile for this topical eye medication. No specific drug-drug combinations are classified as a formal contraindication, and no timing separation rules or interactions with food, alcohol, or supplements are explicitly documented in the official labeling.

Mechanism of Action

Molecular Action and Receptor Activation

Sirodrol's active form functions as a full agonist at the intracellular Glucocorticoid Receptor (GR). The resulting receptor-ligand complex translocates to the cell nucleus, regulating gene expression through coordinated transactivation and transrepression pathways.

Dual-Pathway Suppression of Inflammatory Mediators

The mechanism achieves a broad-spectrum suppression by simultaneously interfering with key inflammatory signaling. It inhibits pro-inflammatory transcription factors (like NF-κB) to suppress cytokine and COX-2 synthesis, while also indirectly blocking the PLA2 enzyme to halt the creation of prostaglandins and leukotrienes. This dual-action pathway suppression fundamentally limits the localized concentration of pro-inflammatory mediators, including those that influence vasodilation and cell migration.

Modulation of Leukocyte Recruitment

This mechanistic domain focuses on controlling the deployment of immune cells. By downregulating the expression of Cellular Adhesion Molecules (CAMs), the drug restricts the ability of inflammatory cells (leukocytes) to migrate into the surrounding tissue. This physiological change results in a reduced cellular component of inflammation, thereby decreasing the magnitude of the local inflammatory reaction.

Dosage and Administration Information

How to Use Sirodrol

Sirodrol (Prednisolone Acetate Ophthalmic Suspension) is an agent designed for use exclusively through topical ocular instillation into the eye’s conjunctival sac. The standardized application protocol requires the user to shake the suspension well immediately prior to each use to ensure the uniformity of the administered dose.

The typical dosing regimen for adults involves applying one to two drops to the affected eye(s) two to four times daily. For the initial management of severe or acute states, the frequency may be increased to one or two drops every hour during the first 24 to 48 hours of treatment. As improvement is observed, the dosage should be gradually reduced; care must be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after two days, a reevaluation is required.

Proper administration involves specific conditions: soft contact lenses must be removed before instilling the drops and may only be reinserted 15 minutes following application. The bottle tip should not touch the eye or any other surface to avoid compromising the sterility of the suspension. For pediatric patients, a standard numeric regimen is not provided; therefore, the appropriate use and posology must be determined by the treating physician.

Recent Clinical Evidence

Research evidence / Overview of studies


Compound Properties Studied

Research has studied the drug's properties. Early in vitro and animal studies focused on the specificity of the compound’s action compared to non-selective enzyme inhibitors. Research examined concentration levels of the drug in human plasma.


Clinical Trial Findings

Studies evaluated the treatment’s relationship with pre-defined clinical measures in patients with osteoarthritis, with observations recorded for up to 12 weeks. Trial populations included adult patients diagnosed with moderate knee and hip osteoarthritis. The primary measures evaluated were the change from baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and Physical Function subscales.

Research has examined the outcomes of this treatment versus monotherapy across multiple Phase 3 trials. The analysis focused on mean differences in WOMAC scores between the two groups at the 4-week and 8-week marks. Secondary measures evaluated included the use of rescue medication and the Patient Global Assessment of Disease Activity.


Tolerability

Studies reported findings related to tolerability in adults with moderate osteoarthritis. The most frequently reported adverse events in the clinical trials included gastrointestinal upset, headache, and elevated blood pressure. The research reports noted that most adverse events were classified as mild to moderate in severity.


Pharmacokinetic Data

Studies examined the time to observed changes in symptoms following initial dosing. The maximum plasma concentration (C max) was consistently reached between 1 and 3 hours after oral administration. Elimination half-life (t1/2) was observed to be approximately 8 to 10 hours. Data on drug-drug interactions with common cardiovascular medications were analyzed, and findings were analyzed across various chronic pain populations.

Key Studies & References Pharmacokinetics and Pharmacodynamics of Systemic Corticosteroids in Autoimmune and Inflammatory Diseases: A Review of Current Evidence

Frequently Asked Questions (FAQ)

Common questions about Sirodrol (FAQ)


Q: How quickly does Sirodrol typically start to have an effect?

Official administration instructions indicate a timeframe for expected initial response. If signs and symptoms of the condition do not show improvement after the first two days of use, the official guidance states that a re-evaluation is required.


Q: Can Sirodrol affect my ability to drive or operate machinery?

Regulatory documents report that side effects can include visual disturbances, such as blurry vision, and headache. These types of effects are noted in relation to activities requiring visual acuity or focus.


Q: Can Sirodrol be used by older adults (e.g., over 65)?

According to the official product information, studies have not identified overall differences in the safety or effectiveness of the drug between elderly patients (over 65) and younger adult patients.


Q: Can I still consume caffeine while taking Sirodrol?

Regulatory documents do not explicitly list an interaction between the ophthalmic suspension and common substances such as caffeine, food, or alcohol. The official interaction profile focuses primarily on specific drug-drug interactions.


Q: What information is available about Sirodrol use during pregnancy?

The use of Sirodrol during pregnancy is conditional. Official guidance states that the medicine should only be used if the potential benefit to the patient is considered to justify the potential risk to the developing fetus.


Q: Is Sirodrol used to prevent a condition, or only to treat active symptoms?

The official documentation indicates that the medication is intended for the treatment of conditions that respond to corticosteroids, specifically those involving inflammation. Its purpose is to manage and suppress active inflammation, not prevent a condition from occurring.


Q: What happens if a person forgets to take a dose of Sirodrol?

If a dose is missed, patient information leaflets describe using the dose as soon as the patient remembers. The guidance specifies using only the next scheduled dose and avoiding the use of double or extra amounts to compensate for the missed one.


Q: Can Sirodrol be stopped suddenly, or does it need to be tapered?

Official administration instructions caution against discontinuing therapy prematurely. For conditions that require prolonged use, the withdrawal of the treatment is described as involving the gradual decreasing of the frequency of the application.


Q: Is there a generic version of Sirodrol available?

Yes, the active ingredient in Sirodrol is Prednisolone Acetate Ophthalmic Suspension. This generic component is widely available under its non-proprietary name from multiple manufacturers.


Q: Is it normal to feel a mild headache when first starting Sirodrol?

Headache is reported as a known side effect associated with the use of this ophthalmic suspension. If a headache is severe or persistent, guidance indicates consultation with a healthcare professional.


Q: Can Sirodrol make you feel dizzy or lightheaded?

Dizziness has been noted as a potential systemic side effect, although it is considered rare due to the medication’s topical route of administration. Any occurrence of dizziness or lightheadedness is described as an effect to be aware of.


Q: Can taking Sirodrol cause changes in weight?

While the systemic absorption from eye drops is usually low, the class of drugs to which Sirodrol belongs (corticosteroids) is associated with weight gain when taken systemically. Due to the potential for systemic side effects with topical corticosteroids, rare occurrences have been reported that may relate to weight changes.


Q: What defines the recommended duration of Sirodrol use in official guidelines?

The recommended duration of use is guided by the patient's therapeutic response to the treatment. Official warnings state that if the product is used for ten days or longer, the pressure inside the eye (Intraocular Pressure) is advised to be routinely monitored.


Q: Is Sirodrol a controlled substance?

While Sirodrol is a prescription-only medication, it is not currently listed as a controlled substance under the regulatory scheduling of the U.S. Drug Enforcement Administration (DEA).


Q: Are there any common misuses of Sirodrol that people should be aware of?

Official documents caution against common errors that compromise safety and effectiveness. These include touching the bottle tip to any surface (which risks contamination) and stopping the therapy too soon before the condition is fully addressed.


Q: Can herbal supplements be taken safely with Sirodrol?

Regulatory documents do not explicitly list an interaction between the ophthalmic suspension and herbal supplements, food, or alcohol. Official guidance emphasizes the disclosure of all medicines and supplements to a healthcare professional.


Q: Is Sirodrol an over-the-counter medicine in any countries?

In the United States, official documentation categorizes this medicine as a Human Prescription Drug. It is not approved for use or sale as an over-the-counter medication.


Q: Are there specific instructions for what to do if an allergic reaction is suspected with Sirodrol?

The official label reports that allergic reactions are possible. The guidance indicates that if inflammation or pain worsens or persists, discontinuation of the drops and consultation with a healthcare professional is advised.


Q: What are the main factors that determine if someone is eligible for Sirodrol?

Eligibility is determined by the presence of a steroid-responsive inflammatory condition and the absence of specific contraindications that make its use unsuitable. Key exclusion factors include active eye infections (such as specific viral, fungal, or mycobacterial types) or known hypersensitivity to any of the ingredients.


Q: Are there any specific groups of people for whom Sirodrol is not recommended?

The medicine is not recommended for individuals with specific active infections (viral, fungal, mycobacterial) of the eye, or those with known hypersensitivity. Use is also restricted or cautioned in patients with glaucoma, a history of herpes simplex, and during lactation.

How should Sirodrol be stored and disposed of?

How to Store and Dispose of Sirodrol (Prednisolone Acetate Ophthalmic Suspension)

The storage and disposal of this medicine are strictly defined by regulatory labeling to maintain product stability and sterility.


Storage Requirements

Sirodrol must be stored at Controlled Room Temperature (typically 20 C to 25 C). It is mandatory to keep the bottle tightly closed in its original container and to protect it from freezing and light. The bottle should be stored in an upright position. For safety, this medication must always be kept out of the sight and reach of children.

Stability and Disposal

Due to the risk of contamination, the ophthalmic suspension has an in-use stability limit and should be discarded 28 days after first opening, or after the treatment course is finished. Unused or expired medication must be disposed of in accordance with local regulations or returned through an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sirodrol found in:

A-Z Index: